ReviewJournal of neuroinflammation2026
Epigenetic mechanisms in traumatic brain injury: a focus on astrocytes and therapeutic implications.
Review in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Traumatic brain injury (TBI) triggers complex molecular and cellular responses that persist well beyond the initial injury. Neuroinflammation is a prominent feature of the post-injury response and a significant contributor to progressive neuronal dysfunction and increased risk of chronic neurodegeneration. Epigenetic mechanisms have emerged as important regulators of the injury response. Astrocytes are increasingly recognized as key mediators of this epigenetic regulation. Injury-induced epigenetic reprogramming in astrocytes may perpetuate maladaptive inflammatory and metabolic states, thereby increasing vulnerability to delayed neurodegeneration. Preclinical studies suggest that pharmacologic or genetic modulation of epigenetic regulators can improve outcomes after experimental TBI. However, clinical translation remains constrained by limited cell-type specificity and potential off-target effects. This review evaluates current evidence on epigenetic regulation after TBI, with an emphasis on astrocyte-centered mechanisms linking acute injury to chronic pathology. We further discuss key translational challenges and highlight emerging precision strategies aimed at cell-type-specific, temporally controlled epigenetic modulation to mitigate long-term neurological consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.